Month: July 2010

Miraculins Inc announces that the United States Patent and Trademark Office has issued US Patent 7,754,495 entitled “Methods for Early Diagnosing of an Increased Risk of Preeclampsia”.

A recent study published in the journal Clinical Chemistry found that seven leading commercial methods produce results of mixed accuracy when compared to well-established techniques.

Asuragen Inc and Life Technologies Corp announced today that they have achieved CE-marking and commercial launch in Europe of the BCR/ABL1 Quant Test.